NicaraguaTuberculosis profile
Population  2015 6.1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.15 (0.12–0.19) 2.5 (1.9–3.1)
Mortality (HIV+TB only) 0.028 (<0.01–0.086) 0.46 (0.04–1.4)
Incidence  (includes HIV+TB) 3.1 (2.4–3.9) 51 (39–64)
Incidence (HIV+TB only) 0.15 (0.12–0.2) 2.5 (1.9–3.2)
Incidence (MDR/RR-TB)** 0.078 (0.034–0.12) 1.3 (0.56–2)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.15 (0.085–0.22) 1.1 (0.66–1.5) 1.2 (0.75–1.7)
Males 0.14 (0.093–0.19) 1.7 (1.3–2.1) 1.8 (1.4–2.3)
Total 0.3 (0.21–0.38) 2.8 (2.4–3.2) 3.1 (2.4–3.9)
TB case notifications, 2015  
Total cases notified 2 705
Total new and relapse 2 465
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 94%
          - % pulmonary 87%
          - % bacteriologically confirmed among pulmonary 79%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.06 (0.04–0.09)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 117 5%
          - on antiretroviral therapy 115 98%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  64
(30–97)
Estimated % of TB cases with MDR/RR-TB 0.94% (0–2.3) 12% (7.3–18)  
% notified tested for rifampicin resistance 19% 69% 709
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 36, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 29, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 85% 1 577
Previously treated cases, excluding relapse, registered in 2014 78% 77
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 78% 9
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 6%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
44% (41–48)
TB financing, 2016  
National TB budget (US$ millions) 9.5
Funding source: 54% domestic, 26% international, 20% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-03-24 Data: www.who.int/tb/data